By Fineline Cube Everest Medicines (HKG: 1952) announced positive topline results from its Phase IIa study of VIS-101, an investigational dual-functional biologic targeting VEGF-A and Ang-2 for wet age-related macular degeneration (wAMD). The data demonstrated rapid onset of action, potent and durable therapeutic response, and favorable safety, validating its potential as a “best-in-class” therapy for long-term durability in retinal vascular diseases.
Phase IIa Study Results
| Endpoint | VIS-101 Performance | Clinical Significance |
|---|---|---|
| Onset of Action | Rapid | Immediate visual acuity benefits vs. standard of care |
| Efficacy | Potent and durable therapeutic response | Reduced injection frequency potential |
| Safety/Tolerability | Favorable profile | Supports long-term chronic administration |
| Best-in-Class Potential | Validated | Dual-target mechanism vs. monotherapy alternatives |
Study Design: Phase IIa trial in wAMD patients; data supports expansion to diabetic macular edema (DME) and retinal vein occlusion (RVO)
Product Profile & Mechanism
| Attribute | VIS-101 Specification |
|---|---|
| Mechanism | Dual inhibition of VEGF-A (vascular permeability) + Ang-2 (vascular stability) |
| Format | Novel biologic; investigational ophthalmic injectable |
| Differentiation | Addresses both pathological angiogenesis and vascular destabilization vs. anti-VEGF monotherapies |
| Target Indications | wAMD (lead), DME, RVO |
| Expected Benefit | More enduring therapeutic effect; reduced treatment burden |
Scientific Rationale: Ang-2 inhibition stabilizes vasculature compromised by VEGF-driven neovascularization, potentially extending durability beyond first-generation anti-VEGF agents (ranibizumab, aflibercept).
Licensing & Geographic Rights
| Element | Detail |
|---|---|
| Licensor | Visara (subsidiary of NovaBridge Biosciences, NASDAQ: NBP) |
| Licensee | Everest Medicines (HKG: 1952) |
| Territory | Greater China, Singapore, South Korea, select Southeast Asian countries |
| Rights | Exclusive clinical development, manufacturing, commercialization |
| Deal Date | October 2025 |
| Deal Terms | Not disclosed; typical milestone/royalty structure for Phase II assets |
Market Context & Competitive Position
| Factor | Implication |
|---|---|
| wAMD Market Size | Greater China $3+ billion annually; growing elderly population drives incidence |
| Standard of Care | Anti-VEGF monotherapies (aflibercept, ranibizumab biosimilars) require monthly/bimonthly injections |
| Durability Gap | ~40% of patients lose vision between injections; VIS-101 dual-target approach addresses unmet need for extended dosing intervals |
| Competitive Landscape | Faricimab (Roche) first dual Ang-2/VEGF-A approved; VIS-101 positions as regional alternative with potentially differentiated profile |
| Pipeline Synergy | Everest’s ophthalmology portfolio includes other retinal assets; VIS-101 anchors wAMD franchise |
- Development Pathway: Phase IIb/III initiation expected 2026; potential for accelerated NMPA review given best-in-class data and unmet need in China
- Commercial Outlook: Peak sales potential $500+ million in licensed territories assuming biannual dosing advantage and competitive pricing vs. faricimab
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for VIS-101. Actual results may differ due to Phase III trial outcomes, competitive dynamics with faricimab, and reimbursement negotiations in Greater China markets.-Fineline Info & Tech